An AllTrials project

NCT06159166: An ongoing trial by Johns Hopkins University

This trial is ongoing. It must report results 2 years, 5 months from now.

Full data

Full entry on ClinicalTrials.gov NCT06159166
Title A Phase 1/2a Open-label, Multicenter Dose Finding Study to Evaluate the Safety and Anti-tumor Activity of Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Feb. 12, 2024
Completion date Nov. 15, 2027
Required reporting date Nov. 14, 2028, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov May 29, 2026
Days late None